Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Semaglutide, a GLP-1 receptor agonist, has emerged as a promising agent in cardiovascular disease management, particularly for patients with obesity and diabetes. Recent studies have demonstrated significant benefits of Semaglutide beyond glycemic control, including reduced major adverse cardiovascu...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | American Heart Journal Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666602225000217 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850040451282763776 |
|---|---|
| author | Celestine Odigwe Rajasekhar Mulyala Haijra Malik Brent Ruiz Mariam Riad Mohammad As Sayiadeh Sanchitha Honganur Alexis Parks Mustafeez Ur Rahman Nasser Lakkis |
| author_facet | Celestine Odigwe Rajasekhar Mulyala Haijra Malik Brent Ruiz Mariam Riad Mohammad As Sayiadeh Sanchitha Honganur Alexis Parks Mustafeez Ur Rahman Nasser Lakkis |
| author_sort | Celestine Odigwe |
| collection | DOAJ |
| description | Semaglutide, a GLP-1 receptor agonist, has emerged as a promising agent in cardiovascular disease management, particularly for patients with obesity and diabetes. Recent studies have demonstrated significant benefits of Semaglutide beyond glycemic control, including reduced major adverse cardiovascular events (MACE), improvements in heart failure symptoms, and weight reduction. Notably, the STEP-HFpEF trial highlighted improved exercise capacity and a reduction in NT-proBNP levels, offering a novel therapeutic pathway for heart failure management. Additionally, Semaglutide has shown anti-inflammatory effects, reducing C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α), thereby mitigating atherosclerotic risks. Moreover, the SELECT trial demonstrated Semaglutide's cardiovascular benefits in non-diabetic, obese patients, suggesting that its effects extend beyond weight loss. These findings represent a potential paradigm shift in cardiovascular risk management, although access and affordability remain key challenges. |
| format | Article |
| id | doaj-art-b812d40c8b1e411e81c00f8e9adb8c91 |
| institution | DOAJ |
| issn | 2666-6022 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Heart Journal Plus |
| spelling | doaj-art-b812d40c8b1e411e81c00f8e9adb8c912025-08-20T02:56:06ZengElsevierAmerican Heart Journal Plus2666-60222025-04-015210051810.1016/j.ahjo.2025.100518Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on SemaglutideCelestine Odigwe0Rajasekhar Mulyala1Haijra Malik2Brent Ruiz3Mariam Riad4Mohammad As Sayiadeh5Sanchitha Honganur6Alexis Parks7Mustafeez Ur Rahman8Nasser Lakkis9Division of Cardiovascular Disease, Department of Medicine, University of South Alabama, United States of AmericaDivision of Cardiovascular Disease, Department of Medicine, University of South Alabama, United States of AmericaDivision of Cardiovascular Disease, Department of Medicine, University of South Alabama, United States of AmericaDivision of Cardiovascular Disease, Department of Medicine, University of South Alabama, United States of AmericaDivision of Cardiovascular Disease, Department of Medicine, University of South Alabama, United States of AmericaDivision of Cardiovascular Disease, Department of Medicine, University of South Alabama, United States of AmericaDivision of Cardiovascular Disease, Department of Medicine, University of South Alabama, United States of AmericaDivision of Cardiovascular Disease, Department of Medicine, University of South Alabama, United States of AmericaDivision of Cardiovascular Disease, Department of Medicine, University of South Alabama, United States of AmericaCorresponding author at: Division of Cardiovascular Disease, Department of Medicine, University of South Alabama, 2451 University Hospital Drive, Mastin 400A, Mobile, AL 36617, United States of America.; Division of Cardiovascular Disease, Department of Medicine, University of South Alabama, United States of AmericaSemaglutide, a GLP-1 receptor agonist, has emerged as a promising agent in cardiovascular disease management, particularly for patients with obesity and diabetes. Recent studies have demonstrated significant benefits of Semaglutide beyond glycemic control, including reduced major adverse cardiovascular events (MACE), improvements in heart failure symptoms, and weight reduction. Notably, the STEP-HFpEF trial highlighted improved exercise capacity and a reduction in NT-proBNP levels, offering a novel therapeutic pathway for heart failure management. Additionally, Semaglutide has shown anti-inflammatory effects, reducing C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α), thereby mitigating atherosclerotic risks. Moreover, the SELECT trial demonstrated Semaglutide's cardiovascular benefits in non-diabetic, obese patients, suggesting that its effects extend beyond weight loss. These findings represent a potential paradigm shift in cardiovascular risk management, although access and affordability remain key challenges.http://www.sciencedirect.com/science/article/pii/S2666602225000217Glucagon-like peptide-1SemaglutideAtherosclerotic riskHeart failureInflammation |
| spellingShingle | Celestine Odigwe Rajasekhar Mulyala Haijra Malik Brent Ruiz Mariam Riad Mohammad As Sayiadeh Sanchitha Honganur Alexis Parks Mustafeez Ur Rahman Nasser Lakkis Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide American Heart Journal Plus Glucagon-like peptide-1 Semaglutide Atherosclerotic risk Heart failure Inflammation |
| title | Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide |
| title_full | Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide |
| title_fullStr | Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide |
| title_full_unstemmed | Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide |
| title_short | Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide |
| title_sort | emerging role of glp 1 agonists in cardio metabolic therapy focus on semaglutide |
| topic | Glucagon-like peptide-1 Semaglutide Atherosclerotic risk Heart failure Inflammation |
| url | http://www.sciencedirect.com/science/article/pii/S2666602225000217 |
| work_keys_str_mv | AT celestineodigwe emergingroleofglp1agonistsincardiometabolictherapyfocusonsemaglutide AT rajasekharmulyala emergingroleofglp1agonistsincardiometabolictherapyfocusonsemaglutide AT haijramalik emergingroleofglp1agonistsincardiometabolictherapyfocusonsemaglutide AT brentruiz emergingroleofglp1agonistsincardiometabolictherapyfocusonsemaglutide AT mariamriad emergingroleofglp1agonistsincardiometabolictherapyfocusonsemaglutide AT mohammadassayiadeh emergingroleofglp1agonistsincardiometabolictherapyfocusonsemaglutide AT sanchithahonganur emergingroleofglp1agonistsincardiometabolictherapyfocusonsemaglutide AT alexisparks emergingroleofglp1agonistsincardiometabolictherapyfocusonsemaglutide AT mustafeezurrahman emergingroleofglp1agonistsincardiometabolictherapyfocusonsemaglutide AT nasserlakkis emergingroleofglp1agonistsincardiometabolictherapyfocusonsemaglutide |